所有图片(1)
About This Item
经验公式（希尔记法）:
C20H22N8O5
CAS号:
分子量:
454.44
Beilstein:
70669
EC號碼:
MDL號碼:
分類程式碼代碼:
41116107
NACRES:
NA.21
推荐产品
生物源
synthetic
品質等級
形狀
powder
適合性
suitable for manufacturing use
儲存溫度
−20°C
SMILES 字串
CN(Cc1cnc2nc(N)nc(N)c2n1)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O
InChI
1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1
InChI 密鑰
FBOZXECLQNJBKD-ZDUSSCGKSA-N
基因資訊
human ... DHFR(1719)
正在寻找类似产品? 访问 产品对比指南
一般說明
我们用于生物制药加工的SAFC® 系列优质原料经过严格的质量控制流程，配合记录文件和技术专长帮助我们的客户达到M-Clarity Program规定的要求。
M-Clarity Program
我们全面的上游工艺化学品系列不仅为生物制药生产商提供生产传统和创新治疗药物所需的优质原料，而且帮助他们更快地将产品投放市场并简化监管问题。请相信我们能够为您带来透明的供应链和可靠的全球采购能力，以最佳的法规支持和服务简化您的产品认证。
M-Clarity Program
我们全面的上游工艺化学品系列不仅为生物制药生产商提供生产传统和创新治疗药物所需的优质原料，而且帮助他们更快地将产品投放市场并简化监管问题。请相信我们能够为您带来透明的供应链和可靠的全球采购能力，以最佳的法规支持和服务简化您的产品认证。
抑制胸苷酸合成酶，是一种非选择性的嘌呤从头合成抑制剂，具有显著的毒性特征，包括肝毒性、肺炎和骨髓抑制。强效叶酸拮抗剂。在HL-60人白血病细胞中诱导凋亡。还可用作抗肿瘤剂。
法律資訊
SAFC is a registered trademark of Merck KGaA, Darmstadt, Germany
訊號詞
Danger
危險分類
Acute Tox. 3 Oral - Muta. 2 - Repr. 1B - STOT RE 1
標靶器官
Liver,Bone marrow
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
Roy Fleischmann et al.
Annals of the rheumatic diseases, 74(6), 1132-1137 (2014-08-22)
Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) is used instead of erythrocyte sedimentation rate (DAS28-ESR) to assess rheumatoid arthritis disease activity; however, values for remission and low disease activity (LDA) for DAS28-CRP have not been validated.
Christian S Kaas et al.
Biotechnology journal, 10(7), 1081-1089 (2015-05-13)
Coagulation factor VIII (FVIII) is one of the most complex biopharmaceuticals due to the large size, poor protein stability and extensive post-translational modifications. As a consequence, efficient production of FVIII in mammalian cells poses a major challenge, with typical yields
Anna-Birgitte Aga et al.
Annals of the rheumatic diseases, 74(2), 381-388 (2013-11-29)
To investigate whether baseline disease activity levels and responses in patients with rheumatoid arthritis (RA) changed during the period 2000-2010. Data were provided by the Norwegian disease-modifying antirheumatic drug (NOR-DMARD) study. Patients with inflammatory joint diseases starting new treatment with
Axel Finckh et al.
Arthritis research & therapy, 16(5), 458-458 (2014-10-16)
Calcium pyrophosphate deposition (CPPD) may cause severe arthropathy, major joint destruction and treatment options are limited. The aim of this study was to test the therapeutic efficacy of methotrexate (MTX) in chronic or recurrent CPPD arthropathy. Patients with CPPD arthropathy
Giovanni L Mancardi et al.
Neurology, 84(10), 981-988 (2015-02-13)
To assess in multiple sclerosis (MS) the effect of intense immunosuppression followed by autologous hematopoietic stem cells transplantation (AHSCT) vs mitoxantrone (MTX) on disease activity measured by MRI. We conducted a multicenter, phase II, randomized trial including patients with secondary
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门